Seres Therapeutics Inc (NASDAQ:MCRB) saw a large growth in short interest during the month of April. As of April 28th, there was short interest totalling 3,106,958 shares, a growth of 14.2% from the April 13th total of 2,721,263 shares. Based on an average daily volume of 167,842 shares, the days-to-cover ratio is currently 18.5 days.

Shares of Seres Therapeutics (NASDAQ:MCRB) traded down 0.2523% during trading on Monday, hitting $9.7254. 72,458 shares of the stock traded hands. The company’s 50 day moving average is $10.18 and its 200 day moving average is $10.26. The firm’s market cap is $392.81 million. Seres Therapeutics has a 52-week low of $8.05 and a 52-week high of $35.98.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. The firm had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $3 million. During the same quarter last year, the firm earned ($0.50) earnings per share. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. On average, equities research analysts predict that Seres Therapeutics will post ($2.63) EPS for the current year.

MCRB has been the topic of several recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $20.00 target price on shares of Seres Therapeutics in a report on Tuesday, January 31st. FBR & Co decreased their target price on shares of Seres Therapeutics from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Cantor Fitzgerald set a $16.00 target price on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Tuesday, January 31st. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, February 1st. Finally, Zacks Investment Research lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $23.20.

Large investors have recently added to or reduced their stakes in the company. Ellington Management Group LLC bought a new stake in Seres Therapeutics during the fourth quarter valued at about $107,000. American International Group Inc. boosted its stake in Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 727 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in Seres Therapeutics during the first quarter valued at about $136,000. Bank of Montreal Can boosted its stake in Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 4,829 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in Seres Therapeutics by 74.8% in the first quarter. Citadel Advisors LLC now owns 20,662 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 8,841 shares in the last quarter. 77.62% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Short Interest in Seres Therapeutics Inc (MCRB) Grows By 14.2%” was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/05/22/short-interest-in-seres-therapeutics-inc-mcrb-grows-by-14-2.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

12 Month Chart for NASDAQ:MCRB

Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.